Amphetamine-like compounds

Amphetamine-like compounds are a group of synthetic stimulant drugs structurally derived from phenethylamine, encompassing amphetamine, methamphetamine, dextroamphetamine, lisdexamfetamine, phentermine, MDMA, and related substances[2][3][7]. These drugs act primarily as sympathomimetic amines and central nervous system stimulants, increasing synaptic levels of dopamine, norepinephrine, and serotonin by disrupting their storage, release, uptake, and metabolism through interactions with monoamine transporters (DAT, NET, SERT), VMAT2, monoamine oxidase, and TAAR1[6][7][8][4]. Therapeutically, members of this class are used in the management of attention deficit hyperactivity disorder, narcolepsy, obesity, binge eating disorder, PTSD, and drug dependence; however, because this entry refers to a group of compounds and not a discrete protein, receptor, enzyme, or defined molecular target, it is not considered an appropriate drug target. Amphetamine-like compounds carry substantial risks including abuse, addiction, cardiovascular and psychiatric side effects, drug-drug interactions, and toxicity with misuse[10][4][2][3].

Other names

Amphetamine-type stimulants (ATS)Substituted amphetaminesPhenethylamine derivativesSynthetic stimulantsSympathomimetic amines

Increase release of dopamine and norepinephrine in CNS by promoting efflux and inhibiting reuptake via transporters (DAT, NET, SERT). Inhibition of VMAT2 (vesicular monoamine transporter 2). Inhibition of monoamine oxidase (MAO). Stimulation of TAAR1 receptor (trace amine-associated receptor 1).